Does Anthem (Elevance Health) Cover Addyi (Flibanserin)?

What Is Addyi and Why Does Coverage Matter?

Addyi (flibanserin) is the first FDA-approved non-hormonal treatment for generalized acquired HSDD in premenopausal women, cleared by the FDA in August 2015 [1]. The drug acts as a serotonin 1A agonist and serotonin 2A antagonist, modulating dopaminergic and noradrenergic pathways involved in sexual motivation rather than genital blood flow [2].

The Clinical Case for Flibanserin

The BEGONIA trial (N=1,378) demonstrated that flibanserin 100 mg nightly increased satisfying sexual events (SSEs) by a mean of 2.5 per month versus 1.5 for placebo at 24 weeks, alongside statistically significant reductions in distress scores on the Female Sexual Distress Scale-Revised (FSDS-R) [3]. A pooled analysis of three Phase 3 trials (DAISY, VIOLET, BEGONIA; combined N=2,400+) published in the Journal of Sexual Medicine confirmed consistent SSE benefit across subgroups [4].

Because HSDD affects an estimated 10% of U.S. Women and carries measurable quality-of-life burden documented by the American College of Obstetricians and Gynecologists [5], the question of insurance access is not academic. At $880 per month list price, an uncovered prescription is simply unaffordable for most patients.

FDA Label Restrictions That Affect PA Decisions

The FDA-approved label requires flibanserin be dispensed only through a Risk Evaluation and Mitigation Strategy (REMS) program, the Addyi REMS, because of clinically meaningful interactions with alcohol and CNS depressants [1]. Anthem's medical policies reference the REMS requirement directly. Your prescriber must be REMS-certified, and many PA forms ask for the prescriber's REMS certification number.

Anthem's Default Coverage Policy for Addyi

Anthem (Elevance Health) classifies Addyi as a covered drug under most commercial formularies, subject to strict prior authorization and often a step-therapy requirement. The precise tier and copay vary by employer group contract, but the underlying clinical criteria are drawn from Anthem's specialty pharmacy medical policy, which aligns with the FDA label and ACOG clinical guidance on female sexual dysfunction [5].

Formulary Tier Placement

On most Anthem commercial plans, Addyi sits on a specialty or non-preferred brand tier, corresponding to Tier 4 or Tier 5 depending on plan design. Specialty-tier cost-sharing commonly runs 25 to 33% coinsurance after deductible, which on an $880 list price amounts to $220, $290 per month before any savings programs. Some self-funded employer plans carve out specialty drugs entirely, meaning coverage depends on the specific plan document, not Anthem's default formulary [6].

Prior Authorization Criteria

Anthem's PA template for flibanserin typically requires all of the following:

• Confirmed diagnosis of generalized acquired HSDD in a premenopausal woman, using DSM-5 criteria
• Age 18 or older
• Prescriber REMS certification for the Addyi REMS program
• Documentation that HSDD is not attributable to a co-existing medical condition (e.g., hypothyroidism, genitourinary syndrome of menopause), a psychiatric disorder better explained by another diagnosis, or a concomitant medication (e.g., SSRIs, SNRIs) [7]
• Completion of step therapy if required by the plan (see below)
• Confirmation the patient does not use alcohol regularly, consistent with REMS contraindication language [1]

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states that HSDD diagnosis should follow validated psychometric tools such as the FSFI (Female Sexual Function Index) or the DSDS (Decreased Sexual Desire Screener) [8]. Including completed FSFI or DSDS scores in the PA package strengthens the submission considerably.

Step Therapy Requirements

Many Anthem commercial plans mandate step therapy before approving Addyi. The required steps vary by plan, but the pattern seen most commonly includes:

1. Documentation of at least 8 to 12 weeks of individual or couples psychotherapy or sex therapy from a licensed provider
2. Consideration or trial of hormonal evaluation to rule out treatable endocrine causes
3. A prescriber attestation that non-pharmacologic approaches were inadequate

Because there is no FDA-approved generic or biosimilar for flibanserin, step therapy does not typically require a failed trial of an alternative drug in the same class. The burden is behavioral-intervention documentation, not a prior drug failure [9].

How to Submit an Anthem Prior Authorization for Addyi

Getting the PA right the first time reduces the back-and-forth that delays treatment by weeks.

Documentation Checklist

Assemble the following before your prescriber contacts Anthem's pharmacy or medical management line:

• Office notes establishing the HSDD diagnosis with duration (symptoms present for at least 6 months per DSM-5 criteria) [7]
• Completed FSFI score (score <26.55 indicates dysfunction) or DSDS result [8]
• FSDS-R score documenting personal distress
• Documentation of psychotherapy or counseling attempts, including provider name, dates, and duration
• Lab results ruling out thyroid dysfunction (TSH), low estradiol, or androgen excess
• Prescriber REMS certification confirmation
• Letter of medical necessity from the prescribing clinician

The American Association of Clinical Endocrinologists (AACE) position paper on sexual dysfunction notes that a structured diagnostic workup improves both patient selection and payer approval rates [10]. Submitting incomplete documentation is the single most common reason initial Addyi PAs are denied.

Timeline Expectations

Standard PA decisions under Anthem's commercial plans carry a 3-business-day turnaround for non-urgent requests. Urgent requests (defined as a delay risking serious clinical deterioration) may be adjudicated within 24 to 72 hours under state-mandated timelines. Once approved, most Anthem Addyi authorizations are valid for 12 months, contingent on a continuity-of-benefit review at renewal [6].

What Happens After an Anthem Denial

A denial is not a final answer. Federal and state laws give patients defined appeal rights, and the clinical evidence supporting flibanserin is strong enough to support a well-constructed appeal.

Level 1: Anthem Internal Appeal

File a Level 1 internal appeal within the timeframe stated on the denial letter, commonly 60 to 180 days depending on state law. The appeal must include:

• A written statement from the prescribing clinician explaining why Addyi is medically necessary for this specific patient
• Any additional clinical records not included in the original PA
• Peer-reviewed literature supporting flibanserin for HSDD, including the BEGONIA trial data [3] and the pooled Phase 3 analysis [4]
• The FDA approval document confirming Addyi is indicated for premenopausal women with generalized acquired HSDD [1]

Anthem must acknowledge the appeal within 5 business days and render a decision within 30 days (or 72 hours for urgent appeals) under the ACA internal appeal rules codified at 45 CFR 147.136 [11].

Level 2: External Independent Review

If Anthem upholds the denial internally, the patient has the right to request an external review by a state-certified independent review organization (IRO). In states following ACA external review standards, the IRO decision is binding on the insurer. The IRO reviewer is typically a board-certified physician in gynecology, psychiatry, or endocrinology [11].

The HealthRX Appeal Framework for Addyi denials organizes the argument around three pillars: (1) diagnostic specificity, confirming the patient meets DSM-5 and FDA label criteria precisely; (2) treatment exhaustion, showing all plan-required steps were completed; and (3) clinical necessity, quantifying the patient's FSFI and FSDS-R scores against published impairment thresholds. Plans that require step therapy cannot deny on the basis of an incomplete behavioral trial if documented evidence shows the trial occurred. Citing 42 U.S.C. § 300gg-19 (the ACA appeals provision) in the appeal letter signals procedural awareness that IROs respond to.

State-Specific Protections

Several states, including California, New York, and Illinois, have enacted laws requiring insurers to cover FDA-approved treatments for female sexual dysfunction with formulary parity relative to drugs approved for male sexual dysfunction [12]. If you are in one of these states and Anthem is denying Addyi while covering sildenafil or tadalafil for erectile dysfunction, include a gender-parity argument explicitly in the appeal.

Addyi Cost Without Insurance and Savings Options

Even if PA is denied or pending, patients are not necessarily stuck at the $880 list price.

Manufacturer Savings Card

Sprout Pharmaceuticals, the maker of Addyi, offers a manufacturer savings card that can reduce out-of-pocket cost to as low as $99 per month for commercially insured patients and eligible cash-pay patients. The savings card is not available to Medicare, Medicaid, or TRICARE beneficiaries due to federal anti-kickback statute constraints. Patients can enroll at the Addyi manufacturer website; the card is processed at the pharmacy and does not require Anthem involvement.

GoodRx and Pharmacy Discount Programs

GoodRx and similar discount programs typically show flibanserin cash prices ranging from $820 to $870 per month at major retail pharmacies, offering minimal savings over list price. Specialty pharmacy programs through Anthem's contracted specialty pharmacy (often CuraScript or Accredo depending on plan) may offer slightly lower rates under negotiated contracts [6].

90-Day Supply Consideration

Some Anthem plans allow a 90-day specialty supply through mail-order pharmacy, which may reduce per-unit cost by 10 to 15% compared to three separate 30-day fills. Confirm this option with Anthem's specialty pharmacy before the prescription is written.

Clinical Monitoring and Renewal Requirements

Anthem's PA renewal for Addyi typically requires documented clinical response. The FDA label and the BEGONIA trial protocol both used SSE frequency and FSDS-R distress reduction as the primary endpoints [3].

What Counts as Adequate Response

For PA renewal, prescribers should document:

• Change in SSE frequency from baseline (any increase is clinically meaningful given the baseline rate of roughly 2 to 3 SSEs per month in the trial population) [3]
• FSDS-R score change (a reduction of 4 to 6 points is considered a minimally clinically important difference based on BEGONIA responder analyses) [3]
• Absence of serious adverse events, particularly syncope from the alcohol interaction or hypotension from CNS depressant co-administration

Safety Co-Prescribing Considerations

Flibanserin carries three black-box warnings: hypotension and syncope with alcohol, hypotension and syncope with CYP3A4 inhibitors (e.g., fluconazole, ketoconazole, clarithromycin), and excessive CNS depression with CNS depressants [1]. Anthem's PA renewal forms often ask the prescriber to attest that concurrent CYP3A4 inhibitors are not being used. A 2016 post-marketing study submitted to the FDA found that moderate CYP3A4 inhibitors increased flibanserin AUC by approximately 2-fold, producing clinically significant blood pressure drops [13].

The North American Menopause Society (NAMS) 2022 position statement on sexual health acknowledges flibanserin as an option for premenopausal HSDD but recommends shared decision-making with explicit alcohol counseling before initiation [14].

Addyi for Weight Loss: Does Anthem Cover This Use?

No. Flibanserin has no FDA-approved indication for weight loss and no published clinical trial evidence supporting this use. Anthem, like all major payers, covers drugs only for FDA-approved indications or evidence-supported off-label uses documented in recognized compendia (e.g., DRUGDEX, Clinical Pharmacology) [6]. Weight loss does not appear in any recognized compendium indication for flibanserin. Any PA submitted with a weight-loss diagnosis code will be denied as not medically necessary.

Working With a Telehealth Prescriber and Anthem

Anthem commercial plans generally recognize telehealth-issued prescriptions for flibanserin, provided the prescribing clinician is licensed in the patient's state and REMS-certified. The DEA's 2023 telehealth prescribing rules do not classify flibanserin as a controlled substance, so no in-person visit is federally required for flibanserin prescriptions. State law varies. California, for example, requires an established patient-provider relationship before specialty drugs can be prescribed via telehealth [15].

The prescriber must submit the PA regardless of whether the visit was in-person or virtual. Anthem does not apply a different PA standard based on visit modality.

When Anthem Requires a Peer-to-Peer Review

Anthem may offer or require a peer-to-peer (P2P) review call between the prescribing clinician and an Anthem medical director before issuing a final denial. This call is an opportunity, not a formality.

During the P2P, the prescriber should:

• Reference specific BEGONIA trial data on SSE improvement [3]
• Cite the FSFI and FSDS-R scores for the specific patient
• Confirm REMS compliance
• Confirm all step-therapy requirements have been met
• Note that ACOG supports pharmacologic treatment of HSDD when behavioral interventions have been insufficient [5]

A well-prepared P2P call reverses a substantial proportion of initial Addyi denials at the internal review stage.